$ATTBF Declares William Fleming as CEO, Mike Withrow to Become International Business Lead

VANCOUVER, BRITISH COLUMBIA–(Marketwired – Jan 27, 2015) – Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (OTC PINK:ATTBF)(CSE:ATT), a specialty biotechnology company focused on cultivating, licensing, and marketing proprietary ingredients, bio-similar compounds, equipment, and consulting services to North American medicinal markets, today announced that William (Bill) Fleming, as Chief Executive Officer (CEO) of Abattis Bioceuticals Corp. effective February 1, 2015. He will succeed Mike Withrow, who is resigning his role as CEO and President to become International Business Advisor for Abattis and promote, develops, and manage opportunities for Abattis Bioceuticals Corp.

Mr. Fleming has founded and served as CEO for a number of entrepreneurial companies and has served with senior executive teams dealing with equity and debt financings. Mr. Fleming has developed corporate strategies for a wide range of companies, from family-owned businesses to multi-national companies. Mr. Fleming is a member of the Qalipu Mi’kmaq First Nation and has provided Advisory Consulting services to Health Canada under the Public Health Information Surveillance program. Mr. Fleming is the Founder of Mernova Medicinal Inc., an Aboriginal owned company focused on becoming a Canadian producer of legal marijuana. Mr. Fleming is a graduate of St. Francis Xavier University and a recipient of the Canadian Armed Forces ROTP Scholarship.

Mike Withrow will continue to serve as International Business Advisor for strategic development.

The board thanks Mr. Withrow for his vision in the founding and development of Abattis Bioceuticals Corp., and for the energy he has devoted to bringing the company to a leadership position in the field of botanical medicine analytics and production in the biotech sector. Mr. Withrow will, in his new role as International Business Advisor and strategic development, continue to seek out global opportunities for the expansion of the corporation’s activities.

Jaouad Fichtali was appointed in the role of Chief Technology Officer (CTO) of Abattis effective November 14, 2014, has resigning the position of CTO and will be assuming the role of Extraction Advisor effective immediately. This will allow the Company to conserve resources until the time when a CTO becomes vital.

Incentive Stock Options

The Company also announces that its Board of Directors has granted incentive stock options to purchase up to 175,000 common shares of the Company at a price of $0.16 per share for a period of five years to its directors, officers and consultants. The grant of stock options is subject to regulatory approval.

About Abattis Bioceuticals Corp.

Abattis is a specialty biotechnology company with capabilities through its wholly owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America. The Company is positioned to capitalize on the fast growing trend toward marijuana legalization in the United States and for medicinal use in Canada and international jurisdictions, by supplying and partnering with companies to employ its mass cultivation systems, extraction equipment/technology, and strategic marketing support to licensed growers. The Company also has an extensive pipeline of high-quality products and intellectual property for the rapidly expanding botanical drug market. We follow strict standard operating protocols, and adhere to the applicable laws of Canada and foreign jurisdictions. For more information, visit the Company’s website at: www.abattis.com.

ON BEHALF OF THE BOARD

Bill Fleming, CEO

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY ORACCURACY OF THIS RELEASE.

FORWARD LOOKING INFORMATION

This press release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company’s Management’s Discussion and Analysis under the Company’s profile on www.sedar.com. While the Company may elect to, it does not undertake to update this information at any particular time.